Achieve Life Sciences Inc
Open
5.56 0.54
Overview
Share price change
24h
Min
5.51
Max
5.73
Income | 4.5M -10M |
|---|---|
EPS | -0.19 |
Employees | 28 |
EBITDA | 4.3M -10M |
Recommendations | Strong Buy |
|---|---|
12 Months Forecast | +139.13% upside |
Next Earnings | 6 sie 2026 |
|---|
Market Cap | -1M 573M |
|---|---|
Previous open | 5.02 |
Previous close | 5.56 |
Achieve Life Sciences Inc Chart
Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.
About Achieve Life Sciences Inc
Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and commercializes cytisinicline for smoking cessation and nicotine addiction. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms. It has license and supply agreement with Sopharma AD and University of Bristol Achieve Life Sciences, Inc. is based in Vancouver, Canada.
